Insights

Dr Millie Long, one of the cochairs of the AIBD 2023 conference, reviews the challenges of positioning therapies for IBD, cautioning that there are no cut-and-dried answers and clinicians must consider the specific needs of each individual...

At AIBD 2023, Dr Rubin reviewed the history of combination therapy for inflammatory bowel disease and explored the potential of combining newer biologic and small molecule therapies to address the understand the immunological basis of IBD and...

Dr Kochar reviews her talk at AIBD 2023 on how the rapid aging of the population with inflammatory bowel disease will present greater challenges to gastroenterologists when choosing therapies and managing the treatment of patients over 65...

Andres Yarur, MD, received this year’s Sherman Emerging Leader Prize for “Excellence in Crohn’s and Colitis.”

Dr Regueiro reviews research from Cleveland Clinic that took a closer look at whether biologics and small molecule therapies increase the risk of major cardiovascular events among patients with inflammatory bowel disease.

Dr El Ouali, from Cleveland Clinic Abu Dhabi, discusses research she and colleagues presented at DDW 2023 on the efficacy of non-antitumor necrosis factor biologics, including vedolizumab, in treatment of patients with stricturing Crohn's...